MP42-16 VARIOUS INCIDENCE RISKS OF SUBSEQUENT MALIGNANCIES IN URINARY TRACT AFTER INITIAL BLADDER CANCER DIAGNOSIS STRATIFIED BY LATENCIES

Abstract

You have accessJournal of UrologyCME1 May 2022MP42-16 VARIOUS INCIDENCE RISKS OF SUBSEQUENT MALIGNANCIES IN URINARY TRACT AFTER INITIAL BLADDER CANCER DIAGNOSIS STRATIFIED BY LATENCIES Shu Wang, Ryan Russell, Michael Phelan, and M. Minhaj Siddiqui Shu WangShu Wang More articles by this author , Ryan RussellRyan Russell More articles by this author , Michael PhelanMichael Phelan More articles by this author , and M. Minhaj SiddiquiM. Minhaj Siddiqui More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002608.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Urinary tract malignancies after bladder cancer (BCa) diagnosis are uncommon, with reported rates of 1.3-13.7%. Early diagnosis and management during follow-up after the initial BCa event are critical. In this study, we aim to capture the incidence risks of subsequent malignancies (SMs) in the urinary tract after BCa diagnosis and investigate the magnitudes stratified by latencies to the development of SMs. METHODS: The Multiple Primary-Standardized Incidence Ratios (MP-SIR) session with SEER Research Plus data was used to search patients diagnosed with BCa as the first primary malignancy between 1975 to 2018. Patients who developed malignancies in the urinary tract at least 3 months after the diagnosis of BCa were considered “SMs”. The relative risks (RRs) of SMs were calculated by the number of observed events/number of expected events (based on U.S. mortality rates) and presented as mean+/-95%CI. RESULTS: 858 patients were identified, 78% (669/858) of which were males. The mean age of Bca diagnosis in this study cohort was 69.46 years, and mean latencies to the development of SMs in the renal pelvis, ureter, and other urinary organs (including urethra, paraurethral glands, and overlapping lesion of urinary organs) were 4.1 years, 3.81 years, and 4.9 years, respectively. The overall RRs of SMs in renal pelvis, ureter, and other urinary organs were 11.02 (95%CI 9.93-12.21), 16.44 (95%CI 14.82-18.18), and 9.95 (95%CI 8.41-11.69), respectively (all p<0.05). We calculated the RR ratios of (1-3years):(3-5years):(5+years) to compare RRs stratified by latencies to the development of SMs. RR ratios were 2.07:1.18:1, 1.24:1.30:1, and 2.59:2.42:1 for renal pelvis, ureter, and other urinary organs, respectively (Figure 1). The RR of SMs dropped dramatically 3 years afterward in the renal pelvis, 5 years in other urinary organs, and stayed high even after 5 years in ureter. CONCLUSIONS: Following the initial diagnosis of BCa, the RRs of SMs vary in different urinary organs when stratified by latencies. This information could be used for follow-up strategy after initial BCa diagnosis and treatment. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e738 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Shu Wang More articles by this author Ryan Russell More articles by this author Michael Phelan More articles by this author M. Minhaj Siddiqui More articles by this author Expand All Advertisement PDF DownloadLoading ...